Related Experiment Video
Updated: Aug 17, 2026
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury
Victoria J Adlam1, Joanne C Harrison, Carolyn M Porteous
1Department of Chemistry, University of Otago, Dunedin, New Zealand.
Abstract:
Mitochondrial oxidative damage contributes to a wide range of pathologies, including cardiovascular disorders and neurodegenerative diseases. Therefore, protecting mitochondria from oxidative damage should be an effective therapeutic strategy. However, conventional antioxidants have limited efficacy due to the difficulty of delivering them to mitochondria in situ. To overcome this problem, we developed mitochondria-targeted antioxidants, typified by MitoQ, which comprises a lipophilic triphenylphosphonium (TPP) cation covalently attached to a ubiquinol antioxidant. Driven by the large mitochondrial membrane potential, the TPP cation concentrates MitoQ several hundred-fold within mitochondria, selectively preventing mitochondrial oxidative damage. To test whether MitoQ was active in vivo, we chose a clinically relevant form of mitochondrial oxidative damage: cardiac ischemia-reperfusion injury. Feeding MitoQ to rats significantly decreased heart dysfunction, cell death, and mitochondrial damage after ischemia-reperfusion. This protection was due to the antioxidant activity of MitoQ within mitochondria, as an untargeted antioxidant was ineffective and accumulation of the TPP cation alone gave no protection. Therefore, targeting antioxidants to mitochondria in vivo is a promising new therapeutic strategy in the wide range of human diseases such as Parkinson's disease, diabetes, and Friedreich's ataxia where mitochondrial oxidative damage underlies the pathology.
Insights
Mitochondria-targeted antioxidants like MitoQ effectively protect against oxidative damage in vivo. This novel strategy shows promise for treating diseases linked to mitochondrial dysfunction.
Area of Science:
- Biochemistry
- Cardiovascular Research
- Neuroscience
Background:
- Mitochondrial oxidative damage is implicated in numerous diseases, including cardiovascular and neurodegenerative disorders.
- Conventional antioxidants struggle with mitochondrial delivery, limiting their therapeutic efficacy.
- Targeting antioxidants specifically to mitochondria offers a potential solution.
Purpose of the Study:
- To develop and evaluate a mitochondria-targeted antioxidant for therapeutic applications.
- To assess the efficacy of MitoQ in preventing in vivo mitochondrial oxidative damage.
- To investigate the potential of mitochondria-targeted therapies for various pathologies.
Main Methods:
- Development of MitoQ, a mitochondria-targeted antioxidant combining a triphenylphosphonium (TPP) cation and ubiquinol.
- Utilizing the mitochondrial membrane potential to concentrate MitoQ within mitochondria.
- Testing MitoQ's efficacy in a rat model of cardiac ischemia-reperfusion injury.
Main Results:
- MitoQ significantly reduced heart dysfunction, cell death, and mitochondrial damage following ischemia-reperfusion.
- Protection was attributed to MitoQ's localized antioxidant activity within mitochondria.
- Untargeted antioxidants and the TPP cation alone did not provide similar protection.
Conclusions:
- Mitochondria-targeted antioxidants are effective in vivo, demonstrating significant protective effects against oxidative damage.
- This approach offers a promising therapeutic strategy for diseases associated with mitochondrial oxidative damage, such as Parkinson's disease, diabetes, and Friedreich's ataxia.
- Targeting antioxidants to mitochondria represents a novel and effective therapeutic avenue for a range of human pathologies.
